Seres Therapeutics Stock Filter Stocks by Fundamentals
| MCRB Stock | USD 0.61 0.02 3.17% |
Seres Therapeutics fundamentals help investors to digest information that contributes to Seres Therapeutics' financial success or failures. It also enables traders to predict the movement of Seres Stock. The fundamental analysis module provides a way to measure Seres Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seres Therapeutics stock.
Seres | Shares Owned by Institutions |
Seres Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Seres Therapeutics from analyzing Seres Therapeutics' financial statements. These drivers represent accounts that assess Seres Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Seres Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 410.2M | 184.2M | 763.9M | 605.2M | 179.2M | 170.2M | |
| Enterprise Value | 383.1M | 105.6M | 633.1M | 604.8M | 265.2M | 251.9M |
Seres Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Seres Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Seres Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Seres Therapeutics' value.| Shares | Susquehanna International Group, Llp | 2023-12-31 | 1.4 M | Woodline Partners Lp | 2023-12-31 | 1.3 M | Handelsbanken Fonder Ab | 2023-12-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 885.3 K | Goldman Sachs Group Inc | 2023-12-31 | 871.7 K | Renaissance Technologies Corp | 2023-12-31 | 817 K | Northern Trust Corp | 2023-12-31 | 770.6 K | Charles Schwab Investment Management Inc | 2023-12-31 | 676.4 K | Qube Research & Technologies | 2023-12-31 | 640.7 K | Flagship Ventures Management, Inc. | 2023-09-30 | 23.1 M | Fmr Inc | 2023-12-31 | 19.4 M |
Seres Fundamentals
| Return On Equity | -5.39 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.90) % | ||||
| Operating Margin | (617.59) % | ||||
| Current Valuation | 182.03 M | ||||
| Shares Outstanding | 151.01 M | ||||
| Shares Owned By Insiders | 5.67 % | ||||
| Shares Owned By Institutions | 59.45 % | ||||
| Number Of Shares Shorted | 18.8 M | ||||
| Price To Earning | (4.04) X | ||||
| Price To Book | 63.84 X | ||||
| Price To Sales | 0.78 X | ||||
| Revenue | 126.33 M | ||||
| Gross Profit | (165.79 M) | ||||
| EBITDA | (92.17 M) | ||||
| Net Income | (113.72 M) | ||||
| Cash And Equivalents | 195.8 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 213.94 M | ||||
| Debt To Equity | 3.35 % | ||||
| Current Ratio | 2.35 X | ||||
| Book Value Per Share | (0.33) X | ||||
| Cash Flow From Operations | (117.35 M) | ||||
| Short Ratio | 4.14 X | ||||
| Earnings Per Share | (0.89) X | ||||
| Price To Earnings To Growth | (0.11) X | ||||
| Target Price | 7.22 | ||||
| Number Of Employees | 233 | ||||
| Beta | 2.25 | ||||
| Market Capitalization | 96.06 M | ||||
| Total Asset | 358.6 M | ||||
| Retained Earnings | (978.24 M) | ||||
| Working Capital | 76.75 M | ||||
| Current Asset | 207.61 M | ||||
| Current Liabilities | 10.92 M | ||||
| Net Asset | 358.6 M |
About Seres Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seres Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seres Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seres Therapeutics' short interest history, or implied volatility extrapolated from Seres Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Seres Therapeutics Piotroski F Score and Seres Therapeutics Altman Z Score analysis. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Seres Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 0.987 | Quarterly Revenue Growth (0.93) | Return On Assets (0.19) | Return On Equity (5.39) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.